Miro1 Reducer Biomarker Strategy for Parkinson's Mitophagy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease lack effective pharmacodynamic biomarkers to monitor treatment response and efficacy, and there is a need for new therapeutic agents and methodologies to address mitochondrial dysfunction associated with the disease.
Innovation Solution
A Miro1 reducer is administered to reduce undesirable levels of the protein Miro1 from damaged mitochondria in cells, accompanied by companion diagnostic assays to determine suitability for treatment, and combined with existing pharmacologic and non-pharmacologic therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Parkinson's disease are used, then existing therapy options are maintained, but effective pharmacodynamic biomarkers to monitor treatment response and efficacy are lacking
Solution Approach 1:
The patent performs preliminary identification and validation of Miro1 as a specific biomarker for Parkinson's disease before clinical application. By establishing Miro1's role in mitochondrial transport and its specific degradation patterns in PD patients beforehand, the patent creates a reliable measurement foundation that enables accurate treatment monitoring without requiring complex real-time discovery processes
Solution Approach 2:
The patent introduces Miro1 as an intermediary biomarker that mediates between the complex pathological processes of Parkinson's disease and measurable treatment outcomes. Miro1 serves as a specific indicator that translates mitochondrial dysfunction and neurodegeneration into quantifiable measurements, enabling reliable treatment monitoring that was previously unavailable
2Reliability
If Miro1 reducer is administered to reduce Miro1 levels in damaged mitochondria, then mitophagy is facilitated and therapeutic effect is achieved, but companion diagnostic assays are required to determine suitability for treatment
Solution Approach 1:
The patent segments the Parkinson's disease diagnostic and treatment system into distinct components: (1) Miro1 level measurement to assess mitochondrial health, (2) companion diagnostic assays to determine treatment suitability, and (3) Miro1 reducer therapy. This segmentation allows each component to be optimized independently while maintaining overall system reliability
Solution Approach 2:
The patent implements a feedback mechanism where companion diagnostic assays measure Miro1 levels and treatment response, providing information that guides continued therapy or adjustment of treatment. This feedback loop ensures therapeutic efficacy by maintaining treatment only for patients who show appropriate biological response to Miro1 reduction
3Adaptability or versatility
If a Miro1 reducer is developed to treat Parkinson's disease, then new therapeutic options are provided, but the defect in Miro1 removal must be accurately detected and measured for diagnosis
Solution Approach 1:
The patent develops Miro1 measurement methodology that serves multiple functions: (1) diagnosing Parkinson's disease by detecting the Miro1 removal defect, (2) determining suitability for Miro1 reducer therapy, and (3) monitoring treatment response. This multi-functional approach increases treatment applicability while managing detection complexity through a unified measurement system
Solution Approach 2:
The patent utilizes the patient's own cells (such as fibroblasts or blood cells) to measure Miro1 levels and assess the Miro1 removal defect. This self-service approach allows diagnosis and treatment selection to be performed using the patient's biological material without requiring complex external testing infrastructure, thereby reducing detection difficulty
Data Source
AI summary
Methods and compositions are provided for the treatment of Parkinson's Disease. Aspects of the methods include administering Miro1 reducer. Also provided are reagents and kits for practicing the subject methods. In some embodiments, a method is provided for reducing undesirable levels of Miro1 in a cell having depolarized or otherwise damaged mitochondria. In some embodiments the cell is in vivo, e.g. in an animal model for PD, in an individual diagnosed with PD, in a clinical trial for treatment of PD, and the like.